Kelvin P. Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kelvin P. Lee has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- Attaya Suvannasankha
Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, School of Medicine, Indiana University, Indianapolis, IN, USA
20 shared publications - Brent Smith
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana
20 shared publications - Brian A. Walker
Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States
20 shared publications - Enze Liu
Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, United States
20 shared publications - Faiza Zafar
Genentech Inc., South San Francisco, California
20 shared publications - Gareth John Morgan
Multiple Myeloma Research Program, Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
20 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 7 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
CD86 expression on patient MM cells prior to CAR T therapy.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 7 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
CD86 expression on patient MM cells prior to CAR T therapy.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 3 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of CAR T cell mitochondrial metabolism.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 3 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of CAR T cell mitochondrial metabolism.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessKey Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Key Resources Table 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 8 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Effect of transient abatacept exposure on MM.1S growth.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 8 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Effect of transient abatacept exposure on MM.1S growth.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 2 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of human and mouse CD28 knockout CAR T cells, and mouse myeloma target cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 2 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of human and mouse CD28 knockout CAR T cells, and mouse myeloma target cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 6 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of short duration of CD28 blockade in mice.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 6 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of short duration of CD28 blockade in mice.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 5 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
In vivo CAR T cell characterization.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 5 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
In vivo CAR T cell characterization.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of human hBCMABBζ CAR T cells and myeloma target cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Characterization of human hBCMABBζ CAR T cells and myeloma target cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Gating Strategies 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Gating strategies used to identify cell populations of interest.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Gating Strategies 1 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
Gating strategies used to identify cell populations of interest.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Fig. 4 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
In vitro CAR T cell proliferation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Fig. 4 from Endogenous CD28 Drives the Persistent Activity of CAR T Cells in Myeloma and Lymphoma Models
In vitro CAR T cell proliferation.